JP2014510047A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510047A5 JP2014510047A5 JP2013552879A JP2013552879A JP2014510047A5 JP 2014510047 A5 JP2014510047 A5 JP 2014510047A5 JP 2013552879 A JP2013552879 A JP 2013552879A JP 2013552879 A JP2013552879 A JP 2013552879A JP 2014510047 A5 JP2014510047 A5 JP 2014510047A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- antibody
- treatment
- patient
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 7
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 229940125798 integrin inhibitor Drugs 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 238000011471 prostatectomy Methods 0.000 claims 1
- -1 radiation Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11001135.0 | 2011-02-11 | ||
| EP11001135 | 2011-02-11 | ||
| PCT/EP2012/000548 WO2012107211A1 (en) | 2011-02-11 | 2012-02-07 | Anti-alpha-v integrin antibody for the treatment of prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016250652A Division JP6488273B2 (ja) | 2011-02-11 | 2016-12-26 | 前立腺癌治療のための抗アルファ−ｖインテグリン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510047A JP2014510047A (ja) | 2014-04-24 |
| JP2014510047A5 true JP2014510047A5 (enExample) | 2015-04-02 |
| JP6320042B2 JP6320042B2 (ja) | 2018-05-09 |
Family
ID=45569571
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013552879A Active JP6320042B2 (ja) | 2011-02-11 | 2012-02-07 | 前立腺癌治療のための抗アルファ−ｖインテグリン抗体 |
| JP2016250652A Expired - Fee Related JP6488273B2 (ja) | 2011-02-11 | 2016-12-26 | 前立腺癌治療のための抗アルファ−ｖインテグリン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016250652A Expired - Fee Related JP6488273B2 (ja) | 2011-02-11 | 2016-12-26 | 前立腺癌治療のための抗アルファ−ｖインテグリン抗体 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9555110B2 (enExample) |
| EP (2) | EP3415162A1 (enExample) |
| JP (2) | JP6320042B2 (enExample) |
| KR (2) | KR102103701B1 (enExample) |
| CN (1) | CN103347540B (enExample) |
| AU (2) | AU2012216145B2 (enExample) |
| CA (1) | CA2827052C (enExample) |
| DK (1) | DK2672994T3 (enExample) |
| EA (1) | EA032117B1 (enExample) |
| ES (1) | ES2683347T3 (enExample) |
| HR (1) | HRP20181212T1 (enExample) |
| HU (1) | HUE037212T2 (enExample) |
| IL (1) | IL227687B (enExample) |
| LT (1) | LT2672994T (enExample) |
| MX (2) | MX385144B (enExample) |
| PL (1) | PL2672994T3 (enExample) |
| PT (1) | PT2672994T (enExample) |
| RS (1) | RS57524B1 (enExample) |
| SG (1) | SG192667A1 (enExample) |
| SI (1) | SI2672994T1 (enExample) |
| TR (1) | TR201810294T4 (enExample) |
| WO (1) | WO2012107211A1 (enExample) |
| ZA (1) | ZA201306807B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57524B1 (sr) | 2011-02-11 | 2018-10-31 | Merck Patent Gmbh | Anti-alfa-v integrin antitelo za tretman kancera prostate |
| EP3193927B1 (en) | 2014-09-17 | 2020-11-25 | Merck Patent GmbH | A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof |
| SG11201702132WA (en) | 2014-09-17 | 2017-04-27 | Merck Patent Gmbh | A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases |
| US20190144547A1 (en) | 2015-11-23 | 2019-05-16 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
| AU2016360661B2 (en) * | 2015-11-23 | 2023-12-14 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
| WO2024137442A1 (en) | 2022-12-21 | 2024-06-27 | Gilead Sciences, Inc. | Combination therapy for treating cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2204890T3 (es) | 1991-03-06 | 2004-05-01 | Merck Patent Gmbh | Anticuerpos monoclonales humanizados. |
| US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| PT719859E (pt) | 1994-12-20 | 2003-11-28 | Merck Patent Gmbh | Anticorpo monoclonal anti-alfa v-integrina |
| DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| DE19842415A1 (de) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| EP1998266A3 (en) | 2001-02-19 | 2009-02-11 | Merck Patent GmbH | Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity |
| DE10163459A1 (de) | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| EP2351583A1 (en) | 2002-11-26 | 2011-08-03 | Facet Biotech Corporation | Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| KR20120089307A (ko) | 2004-02-12 | 2012-08-09 | 메르크 파텐트 게엠베하 | 항－ｅｇｆｒ 항체들의 고농축 액체 제형물 |
| KR20060002667A (ko) | 2004-07-03 | 2006-01-09 | 삼성전자주식회사 | 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브 |
| US8202465B2 (en) | 2004-11-03 | 2012-06-19 | Honeywell International Inc. | Preferential curing technique in compression molding of fiber reinforced composites |
| US20070025889A1 (en) | 2005-07-28 | 2007-02-01 | Pcbu Business Services, Inc. | Reactors, reactor assemblies and production processes |
| DE102005062440B4 (de) | 2005-12-27 | 2011-02-24 | Lts Lohmann Therapie-Systeme Ag | Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen |
| DK2270050T3 (da) | 2005-12-30 | 2013-08-12 | Merck Patent Gmbh | Anti-CD19-antistoffer med nedsat immunogenicitet |
| AU2007207465B2 (en) | 2006-01-18 | 2012-12-06 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
| US8715718B2 (en) | 2006-07-14 | 2014-05-06 | Rutgers, The State University Of New Jersey | Extracellular matrix production from nanoscale substrate |
| DK2167128T3 (da) * | 2007-07-17 | 2012-12-03 | Merck Patent Gmbh | Fremstillede anti-alfa-v-integrin hybrid-antistoffer |
| WO2009026328A2 (en) | 2007-08-21 | 2009-02-26 | Immune Disease Institute, Inc. | Methods of delivery of agents to leukocytes and endothelial cells |
| US20120004129A1 (en) * | 2008-12-23 | 2012-01-05 | Merck Patent Gmbh | Biomarkers for inhibitors with anti-angiogenic activity |
| EA032728B1 (ru) | 2009-08-19 | 2019-07-31 | Мерк Патент Гмбх | Антитела для выявления комплексов интегрина в ffpe материале |
| EP2498821A1 (en) | 2009-11-13 | 2012-09-19 | Merck Patent GmbH | Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents |
| WO2011162933A1 (en) * | 2010-06-04 | 2011-12-29 | Immunogen, Inc. | Anti-integrin immunoconjugate dosing regimens |
| RS57524B1 (sr) | 2011-02-11 | 2018-10-31 | Merck Patent Gmbh | Anti-alfa-v integrin antitelo za tretman kancera prostate |
| JP6035716B2 (ja) | 2011-08-26 | 2016-11-30 | ソニー株式会社 | 情報処理システム及び情報処理方法 |
| WO2014143383A1 (en) | 2013-03-13 | 2014-09-18 | Agilent Technologies, Inc. | Transposome tethered to a gene delivery vehicle |
| EP3041863A4 (en) | 2013-09-05 | 2017-08-16 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
-
2012
- 2012-02-07 RS RS20180926A patent/RS57524B1/sr unknown
- 2012-02-07 EA EA201391147A patent/EA032117B1/ru not_active IP Right Cessation
- 2012-02-07 SI SI201231356T patent/SI2672994T1/sl unknown
- 2012-02-07 CN CN201280008336.1A patent/CN103347540B/zh active Active
- 2012-02-07 PT PT12702990T patent/PT2672994T/pt unknown
- 2012-02-07 MX MX2017014184A patent/MX385144B/es unknown
- 2012-02-07 DK DK12702990.8T patent/DK2672994T3/en active
- 2012-02-07 US US13/984,669 patent/US9555110B2/en active Active
- 2012-02-07 HR HRP20181212TT patent/HRP20181212T1/hr unknown
- 2012-02-07 MX MX2013009062A patent/MX352025B/es active IP Right Grant
- 2012-02-07 LT LTEP12702990.8T patent/LT2672994T/lt unknown
- 2012-02-07 SG SG2013060140A patent/SG192667A1/en unknown
- 2012-02-07 JP JP2013552879A patent/JP6320042B2/ja active Active
- 2012-02-07 CA CA2827052A patent/CA2827052C/en active Active
- 2012-02-07 EP EP18170936.1A patent/EP3415162A1/en not_active Withdrawn
- 2012-02-07 AU AU2012216145A patent/AU2012216145B2/en not_active Ceased
- 2012-02-07 KR KR1020197011392A patent/KR102103701B1/ko not_active Expired - Fee Related
- 2012-02-07 TR TR2018/10294T patent/TR201810294T4/tr unknown
- 2012-02-07 HU HUE12702990A patent/HUE037212T2/hu unknown
- 2012-02-07 WO PCT/EP2012/000548 patent/WO2012107211A1/en not_active Ceased
- 2012-02-07 EP EP12702990.8A patent/EP2672994B1/en active Active
- 2012-02-07 ES ES12702990.8T patent/ES2683347T3/es active Active
- 2012-02-07 PL PL12702990T patent/PL2672994T3/pl unknown
- 2012-02-07 KR KR1020137023946A patent/KR101972533B1/ko not_active Expired - Fee Related
-
2013
- 2013-07-29 IL IL227687A patent/IL227687B/en active IP Right Grant
- 2013-09-10 ZA ZA2013/06807A patent/ZA201306807B/en unknown
-
2016
- 2016-12-26 JP JP2016250652A patent/JP6488273B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-09 US US15/401,971 patent/US20170218070A1/en not_active Abandoned
- 2017-02-14 AU AU2017200998A patent/AU2017200998B2/en not_active Ceased
-
2019
- 2019-01-25 US US16/258,289 patent/US20190263913A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| US20200147084A1 (en) | Tec family kinase inhibitor adjuvant therapy | |
| JP2015534577A5 (enExample) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2009539870A5 (enExample) | ||
| JP2014510047A5 (enExample) | ||
| ES2922378T3 (es) | C. novyi para el tratamiento de tumores sólidos en seres humanos | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2014132009A5 (enExample) | ||
| TWI818120B (zh) | 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療 | |
| JP2017537105A5 (enExample) | ||
| JP7307044B2 (ja) | 逐次的抗癌治療 | |
| JP2020510039A5 (enExample) | ||
| WO2020030977A3 (en) | Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| EP4201424A1 (en) | Antitumor agent and antitumor effect enhancer | |
| RU2011146339A (ru) | Комбинированная терапия с использованием агента (ов) против igfr и специфических ингибиторов igf-1r | |
| EP3976193A1 (en) | Dosing of bispecific t cell engager | |
| RU2728101C2 (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
| CN103347540A (zh) | 用于治疗前列腺癌的抗-α-v整联蛋白抗体 | |
| WO2016181225A3 (en) | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors | |
| JP2020535180A5 (enExample) | ||
| RU2013115739A (ru) | Связывающиеся с sdf-1 нуклеиновые кислоты и их применение при лечении рака | |
| JP2022044827A (ja) | 免疫媒介性がん治療のための組成物及び方法 | |
| Lucas et al. | CTNI-64. PHASE 2 STUDY OF REGORAFENIB IN BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA |